TIDM0Y7T
RNS Number : 3540M
J.P. Morgan Securities LLC
08 May 2020
Ap27
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED
INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal J.P Morgan Securities LLC
trader
Company dealt in Allergan plc
=========================
Class of relevant security Ordinary Share
to which the dealings
being disclosed relate
(Note 1)
=========================
Date of dealing 7 May 2020
=========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 2)
Long Short
Number (%) Number (%)
======= ==== ==== ========= ==== ====
3,689,394
(1) Relevant securities 4,556,431 1.38 1.12
=================== =====================
(2) Derivatives (other 4,232,350
than options) 3,851,379 1.17 1.29
=================== =====================
(3) Options and agreements
to purchase/sell 305,000 0.09 0 0.00
=================== =====================
7,921,744
Total 8,712,810 2.64 2.41
=================== =====================
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 2)
Class of relevant security: Long Short
Number (%) Number (%)
======= ==== ==== ========= ==== ====
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap28
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(Note 4)
Purchases 9,070 192.9900 USD
110 193.0500 USD
100 193.0800 USD
200 193.0991 USD
100 193.1064 USD
25 193.1079 USD
240 193.1136 USD
200 193.1375 USD
200 193.1400 USD
25 193.2158 USD
100 193.3600 USD
33,000 193.6550 USD
35 194.1786 USD
14 194.1900 USD
100 194.2400 USD
17 194.2700 USD
224 194.3598 USD
12 194.3600 USD
60 194.3855 USD
1,700 194.4259 USD
694 194.4350 USD
700 194.4814 USD
1,806 194.5294 USD
2,000 194.5363 USD
16,000 194.5385 USD
800 194.5463 USD
7,600 194.5767 USD
400 194.5800 USD
100 194.6900 USD
100 194.8000 USD
Sales 3 192.9200 USD
4 192.9375 USD
1 192.9600 USD
8,888 192.9900 USD
111 193.0000 USD
172 193.0265 USD
3 193.0700 USD
3 193.0933 USD
2 193.1150 USD
1 193.1200 USD
603 193.2133 USD
314 193.2226 USD
1 193.2300 USD
4 193.2650 USD
4 193.4225 USD
2,301 193.5086 USD
2 193.5350 USD
1 193.5400 USD
18,338 193.6525 USD
33,000 193.6550 USD
1 193.7200 USD
10,269 193.7295 USD
1,001 193.7792 USD
3 193.9100 USD
1 193.9500 USD
5 193.9740 USD
2 193.9750 USD
5 194.0100 USD
3 194.0633 USD
2 194.1500 USD
1 194.1600 USD
1 194.3200 USD
16,000 194.5385 USD
66 194.6607 USD
1 195.1400 USD
==================================== ===================
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, securities unit
e.g. CFD (Note 5) (Note 6) (USD)
(Note 4)
Equity Swaps Long 194 192.9900
33,000 193.6550
Short 16,000 194.5385
====================== =================== ==========
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 4)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
4)
(d) Other dealings (including transactions in respect of new
securities) (Note 3)
Nature of transaction Details Price per unit
(Note 7) (if applicable)
(Note 4)
Ap29
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or relating to the voting rights or future
acquisition or disposal of any relevant securities to which any
derivative referred to on this form is referenced. If
none, this should be stated.
Is a Supplemental Form 38.5(b) attached? (Note 8) YES
Date of disclosure 8 May 2020
Contact name Alwyn Basch
=============================
Telephone number 020 7742 7407
=============================
Name of offeree/offeror Allergan plc
with which connected
=============================
Nature of connection (Note Financial Advisor to Allergan
9) plc
=============================
Ap31
SUPPLEMENTAL FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)
Product Written Number of Exercise Type, e.g. Expiry
name, or purchased relevant price American, date
e.g. call securities (Note European
option to which 2) etc.
the option
or derivative
relates
Put Option Written 300,000 150.00 American 19JUN20
Put Option Written 5,000 140.00 American 19JUN20
============== =============== ========= =========== ========
Notes
1. Where there are open option positions or open derivative
positions (except for CFDs), full details should be given. Full
details of any existing agreements to purchase or to sell must also
be given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosur e requirements, see Rules 8 and
38.5 of the Rules. If in doubt, consult the Panel.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEKZGGKGRKGGZM
(END) Dow Jones Newswires
May 11, 2020 02:00 ET (06:00 GMT)
Allergan (LSE:0Y7T)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Allergan (LSE:0Y7T)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
